Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies

2016 ◽  
Vol 26 (4) ◽  
pp. 413-416 ◽  
Author(s):  
Shelley J.E. Hwang ◽  
Giuliana Carlos ◽  
Shaun Chou ◽  
Deepal Wakade ◽  
Matteo S. Carlino ◽  
...  
Immunotherapy ◽  
2021 ◽  
Author(s):  
Francisco Aya ◽  
E Azucena González-Navarro ◽  
Clara Martínez ◽  
Esther Carcelero ◽  
Ana Arance

Aim: To evaluate the safety of rechallenge with a different anti-PD-1 antibody after an immune-related adverse event (irAE) that has prompted the discontinuation of anti-PD-1 therapy. Patients & methods: We describe two patients with metastatic melanoma who developed potentially disabling and early irAEs following anti-PD-1 treatment. Therapy was discontinued and toxicities resolved with corticosteroids. Results: Rechallenge switching to an alternative anti-PD-1 antibody did not lead to a new or recurrent irAE. Conclusion: Switching to a different anti-PD-1 antibody when resuming therapy after an irAE might be a safe strategy and warrants further investigation. Structural and biological differences between antibodies might explain the different safety outcomes.


2017 ◽  
Vol 31 (8) ◽  
pp. e349-e350 ◽  
Author(s):  
C.W. Kwon ◽  
A.S. Land ◽  
B.R. Smoller ◽  
G. Scott ◽  
L.A. Beck ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document